Continuous Positive Airway Pressure versus High-Flow Nasal Oxygen in Adults with Pneumonia-Related Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis
In brief
CPAP cuts intubation risk by 25% versus high-flow oxygen in pneumonia
Across seven studies involving 1,551 adults with pneumonia-related respiratory failure, CPAP was linked to a 25% lower risk of intubation within 30 days than high-flow nasal oxygen; the reduction persisted in randomized trials. CPAP also delayed intubation, but did not improve survival or shorten hospital stays, and high-flow oxygen remains a reasonable, generally better-tolerated option.
- Journal
- Respiratory medicine (Q1)
- Published
- 14 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Syed Faqeer Hussain Bokhari, Syed Zakria Ali Shah, Hafiz Asad Ullah, Hira Fatima, Mouzma Shafi, Waqar Ali, et al.
- PMID
- 43034002
- DOI
- 10.1016/j.rmed.2026.109297
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (paper of the day, 16 November 2026): Compares CPAP and high-flow oxygen in pneumonia-related respiratory failure
Abstract
BACKGROUND: Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) are both used to avert invasive mechanical ventilation in patients with pneumonia-related acute hypoxemic respiratory failure (AHRF), but head-to-head evidence comparing these two modalities specifically, rather than each against conventional oxygen, remains fragmented. METHODS: We searched major databases for studies enrolling adults with pneumonia-related AHRF, including COVID-19-related pneumonia, managed with CPAP versus HFNO. The prespecified primary outcome was intubation within 30 days; secondary outcomes were time to intubation, in-hospital, 30-day, and 90-day mortality, and length of hospital stay. RESULTS: Seven studies (n=1,551), met the inclusion criteria. CPAP was associated with a significantly lower risk of intubation within 30 days than HFNO (RR 0.75 [0.65-0.86], p<0.0001; I2=33%; moderate certainty of evidence). This benefit was significant among patients with COVID-19 pneumonia (RR 0.75 [0.65-0.86], p<0.0001) but not among those with non-COVID-19 pneumonia (RR 0.67 [0.31-1.45]), although no significant subgroup interaction was detected (p=0.78). CPAP was also associated with a significantly longer time to intubation than HFNO (MD 22.27 hours [16.22-28.33]). No significant differences were observed between CPAP and HFNO for 30-day mortality, 90-day mortality, in-hospital mortality, or length of hospital stay. The reduction in intubation was attenuated but persisted when the analysis was restricted to the four randomized trials (RR 0.81 [0.70-0.95]; I2=0%). CONCLUSIONS: In adults with pneumonia-related AHRF, CPAP probably reduces the risk of intubation compared with HFNO without conferring a mortality advantage or reducing length of stay. HFNO remains a reasonable, generally better-tolerated alternative.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.